Role of Ultrasound and Cross-Sectional Imaging (CT and MRI) in the Characterization of Ovarian Neoplasms: A Prospective Diagnostic Accuracy Study give me Appendices of this thesis topic for synopsis of md radiology
Reading File
The Appendices section for an MD Radiology synopsis on this topic is a standard academic requirement. Here is a complete, ready-to-use set of appendices based on established conventions for prospective diagnostic accuracy studies in radiology.
Searching sources... (running parallel searches for imaging criteria, scoring systems, and consent templates used in ovarian neoplasm studies)
Finding Sources
Searching PubMed
"ovarian neoplasm" AND "ultrasound" AND "MRI" AND diagnostic accuracy
Searching the Web
IOTA ADNEX model O-RADS scoring criteria ovarian mass ultrasound MRI characterization
Here is a complete set of Appendices for your MD Radiology synopsis on this topic. These are structured to meet the standard requirements of most Indian medical university postgraduate synopsis formats (MCI/NMC guidelines).
APPENDICES
APPENDIX I: PROFORMA / DATA COLLECTION SHEET
Study Title: Role of Ultrasound and Cross-Sectional Imaging (CT and MRI) in the Characterization of Ovarian Neoplasms: A Prospective Diagnostic Accuracy Study
PATIENT IDENTIFICATION
| Field | Details |
|---|---|
| Serial No. | |
| Hospital Registration No. | |
| Name (Initials) | |
| Age (years) | |
| Date of Admission | |
| Date of Imaging |
CLINICAL DETAILS
- Chief Complaint: _______________
- Duration of symptoms: _______________
- Menopausal status: Pre-menopausal / Peri-menopausal / Post-menopausal
- Last Menstrual Period (LMP): _______________
- Parity: G__ P__ L__ A__
- Previous pelvic surgery: Yes / No (if yes, details): _______________
- Family history of ovarian / breast / colorectal cancer: Yes / No
- Serum CA-125 (U/mL): _______________
- Serum CEA, AFP, LDH, beta-hCG (if done): _______________
- Risk of Malignancy Index (RMI): _______________
ULTRASOUND FINDINGS (Transabdominal + Transvaginal)
Lesion Characteristics (IOTA Terminology):
| Parameter | Finding |
|---|---|
| Side (Right / Left / Bilateral) | |
| Unilocular / Multilocular / Solid / Mixed | |
| Maximum diameter (cm) | |
| Wall thickness (mm): thin (<3 mm) / thick (≥3 mm) | |
| Septa: Absent / Present; thin (<3 mm) / thick (≥3 mm) | |
| Papillary projections: Absent / Present; No. of projections | |
| Acoustic shadowing: Present / Absent | |
| Internal echogenicity: Anechoic / Low / Ground-glass / Mixed / Hyperechoic | |
| Ascites: None / Mild / Moderate / Massive | |
| Peritoneal deposits: Absent / Present |
IOTA Simple Rules:
- Malignant features (M-features): M1 / M2 / M3 / M4 / M5 (mark all that apply)
- Benign features (B-features): B1 / B2 / B3 / B4 / B5 (mark all that apply)
- Simple Rules result: Benign / Malignant / Inconclusive
IOTA ADNEX Model Risk Score: _______%
Colour Doppler:
- Vascularity: Absent / Present (central / peripheral / both)
- Resistive Index (RI): ___________
- Pulsatility Index (PI): ___________
- Peak Systolic Velocity (PSV): ___________
O-RADS Ultrasound Category (0-5): ___________
CT FINDINGS (Contrast-Enhanced CT Abdomen and Pelvis)
| Parameter | Finding |
|---|---|
| Lesion size (cm) | |
| Morphology: Cystic / Solid / Mixed | |
| Density (HU): Pre-contrast / Post-contrast | |
| Enhancement pattern | |
| Fat content (HU < -20): Present / Absent | |
| Calcification: Present / Absent | |
| Septations: Present / Absent; No./Thickness | |
| Mural nodules / Papillary projections | |
| Peritoneal deposits: Present / Absent | |
| Ascites: Present / Absent | |
| Lymphadenopathy: Present / Absent; stations | |
| Hydronephrosis: Present / Absent | |
| Adjacent organ invasion | |
| Liver / other distant metastases |
MRI FINDINGS (1.5T / 3T MRI Pelvis with contrast)
Protocol used: T1W / T2W / DWI / DCE / Fat-saturation
| Parameter | Finding |
|---|---|
| Lesion size (cm) | |
| T1 signal: Hypointense / Isointense / Hyperintense / Fat-signal | |
| T2 signal: Hypointense (dark) / Intermediate / Hyperintense | |
| T2 dark spot / T2 shading: Present / Absent | |
| DWI restriction: Present / Absent; ADC value (x10⁻³ mm²/s) | |
| Enhancement pattern on DCE: Type I (progressive) / Type II (plateau) / Type III (wash-out) | |
| Papillary projections: Absent / Present | |
| Mural nodules: Absent / Present | |
| Septae characteristics | |
| Ascites / Peritoneal deposits | |
| Lymphadenopathy |
O-RADS MRI Category (0-5): ___________
Radiological Impression: Benign / Borderline / Malignant / Indeterminate
HISTOPATHOLOGICAL FINDINGS (Reference Standard)
- Surgical procedure: Cystectomy / Salpingo-oophorectomy / TAH+BSO / Laparoscopy / USG-guided biopsy
- Gross pathology: _______________
- Microscopic diagnosis: _______________
- WHO Classification: _______________
- FIGO Stage (if malignant): _______________
- Concordance with imaging: Yes / No
APPENDIX II: O-RADS ULTRASOUND SCORING SYSTEM (ACR 2020)
(To be referenced during image reporting)
| O-RADS Category | Description | Malignancy Risk |
|---|---|---|
| 0 | Incomplete evaluation | - |
| 1 | Normal ovary / physiological | Almost 0% |
| 2 | Almost certainly benign | <1% |
| 3 | Low risk of malignancy | 1-10% |
| 4 | Intermediate risk | 10-50% |
| 5 | High risk of malignancy | >50% |
M-features (malignant):
- M1: Irregular solid tumour
- M2: Ascites
- M3: At least four papillary structures
- M4: Irregular multilocular-solid tumour with largest diameter ≥100 mm
- M5: Very high vascularity (colour score 4)
B-features (benign):
- B1: Unilocular cyst
- B2: Presence of solid components where the largest solid component is <7 mm
- B3: Acoustic shadowing
- B4: Smooth multilocular tumour with largest diameter <100 mm
- B5: No blood flow (colour score 1)
APPENDIX III: O-RADS MRI SCORING SYSTEM (ACR 2020)
| O-RADS MRI Score | Description | Malignancy Risk |
|---|---|---|
| 0 | Incomplete | - |
| 1 | Normal ovary | ~0% |
| 2 | Almost certainly benign | <3% |
| 3 | Low risk | 3-<30% |
| 4 | Intermediate risk | 30-<75% |
| 5 | High risk | ≥75% |
Key MRI criteria used:
- Morphology (purely cystic, cystic with solid component, purely solid)
- T2 signal of solid component
- DWI / ADC restriction
- DCE perfusion: Time-Intensity Curve (TIC) pattern
- Papillary projections / mural nodules
- Peritoneal deposits, ascites, lymphadenopathy
APPENDIX IV: IOTA SIMPLE RULES (Reference)
Malignant features (M-features):
| Code | Feature |
|---|---|
| M1 | Irregular solid tumour |
| M2 | Ascites |
| M3 | ≥4 papillary structures |
| M4 | Irregular multilocular-solid tumour ≥10 cm |
| M5 | Very high vascularity (score 4) |
Benign features (B-features):
| Code | Feature |
|---|---|
| B1 | Unilocular |
| B2 | Solid components <7 mm |
| B3 | Acoustic shadowing |
| B4 | Smooth multilocular, <10 cm |
| B5 | No vascularity (score 1) |
Classification:
- If only B-features: Classify as Benign
- If only M-features: Classify as Malignant
- If both or neither: Inconclusive - refer for expert evaluation or MRI
Source: Timmerman D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery. BMJ 2008.
APPENDIX V: WHO CLASSIFICATION OF OVARIAN TUMOURS (5th Edition, 2020) - Summary
Epithelial Tumours:
- Serous: Benign / Borderline / Malignant (Low-grade / High-grade)
- Mucinous: Benign / Borderline / Malignant
- Endometrioid: Benign / Borderline / Malignant
- Clear cell: Benign / Borderline / Malignant
- Brenner / Transitional cell: Benign / Borderline / Malignant
- Seromucinous: Benign / Borderline / Malignant
- Undifferentiated / Dedifferentiated
Sex Cord-Stromal Tumours:
- Granulosa cell tumour (Adult / Juvenile)
- Sertoli-Leydig cell tumour
- Fibroma / Fibrothecoma / Thecoma
Germ Cell Tumours:
- Mature teratoma (Dermoid cyst)
- Immature teratoma
- Dysgerminoma
- Yolk sac tumour
- Mixed germ cell tumour
Metastatic Tumours:
- Krukenberg tumour
- Secondary from colorectal, gastric, breast, endometrial primaries
APPENDIX VI: INFORMED CONSENT FORM
[In English - to be translated into regional language as required by institution]
PATIENT INFORMATION SHEET
Title of Study: Role of Ultrasound and Cross-Sectional Imaging (CT and MRI) in the Characterization of Ovarian Neoplasms: A Prospective Diagnostic Accuracy Study
Principal Investigator: [Name, Designation, Department]
Institution: [Name of Institution]
Introduction:
You are being invited to participate in a research study. Before you decide to take part, it is important that you understand why the research is being done and what it involves. Please read the following information carefully and ask us if anything is unclear.
Purpose of the Study:
You have been referred for imaging of a mass in your pelvis / ovary. As part of this study, you will undergo ultrasound examination, a CT scan, and an MRI scan of your abdomen and pelvis. The purpose of this study is to compare the accuracy of these three imaging tests in identifying the nature (benign or cancerous) of the ovarian mass. The final diagnosis will be confirmed by the surgical specimen / tissue sample.
What Will Happen to Me?
- You will undergo a detailed ultrasound examination (including a transvaginal scan, if required), which takes approximately 20-30 minutes.
- You will undergo a CT scan of the abdomen and pelvis with an intravenous contrast injection.
- You will undergo an MRI of the pelvis with an intravenous gadolinium contrast injection.
- Blood samples (CA-125 and other tumour markers) will be collected as part of routine workup.
- No additional invasive procedure is being done solely for this study. Imaging is part of your standard clinical evaluation.
Risks:
- Ultrasound has no known risks.
- CT involves a small dose of radiation. Contrast dye may rarely cause allergic reactions; the team is equipped to manage these.
- MRI contrast (gadolinium) is generally safe. It should not be used in severe kidney disease.
- All procedures will be performed by experienced radiologists.
Benefits:
- Your participation will help improve the diagnosis of ovarian tumours in future patients.
- You will receive a comprehensive imaging evaluation as part of your care.
Confidentiality:
Your personal information will be kept confidential. Your name will not be used in any publication. Data will be stored in coded form.
Voluntary Participation:
Participation is entirely voluntary. You may withdraw at any time without affecting your medical care.
Contact:
For any queries, please contact: [PI Name, Phone, Email]
Ethics Committee: [IEC Name, Contact]
CONSENT FORM
I, ____________________________________________, aged ________ years,
having read / been explained the above information in a language I understand,
hereby voluntarily consent to participate in the above study.
I understand that I may withdraw at any time without affecting my care.
Signature / Thumb impression of Patient: _________________ Date: ___________
Signature of Witness: _________________ Date: ___________
Signature of Investigator: _________________ Date: ___________
APPENDIX VII: ETHICAL CLEARANCE CERTIFICATE
(To be obtained from Institutional Ethics Committee - IEC)
[Placeholder - attach the original IEC approval letter here]
Required information to be mentioned:
- IEC Registration No. (ECR/XXXXX/Inst/XX/20XX) as per CDSCO/ICMR guidelines
- Protocol No.:
- Date of approval:
- Title of the study (exact):
- Principal Investigator name and designation:
- Duration of study approved:
- Any conditions / recommendations by the committee:
Note: Ethical approval must be obtained from the IEC before enrollment of the first patient. The certificate must bear the stamp, signature of the IEC chairperson, and date.
APPENDIX VIII: MASTER CHART
(To be filled prospectively for each enrolled patient)
| S.No | Reg No. | Age | Menopausal Status | CA-125 | USG Diagnosis | O-RADS US | CT Diagnosis | MRI Diagnosis | O-RADS MRI | Histopathology | Concordance (USG) | Concordance (CT) | Concordance (MRI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||||
| 2 | |||||||||||||
| ... |
APPENDIX IX: KEY TO ABBREVIATIONS
| Abbreviation | Full Form |
|---|---|
| ACR | American College of Radiology |
| ADC | Apparent Diffusion Coefficient |
| ADNEX | Assessment of Different NEoplasias in the adneXa |
| AFP | Alpha-Fetoprotein |
| AUC | Area Under the ROC Curve |
| BSO | Bilateral Salpingo-Oophorectomy |
| CA-125 | Cancer Antigen 125 |
| CE-CT | Contrast-Enhanced Computed Tomography |
| CEA | Carcinoembryonic Antigen |
| CT | Computed Tomography |
| DCE | Dynamic Contrast Enhancement |
| DWI | Diffusion-Weighted Imaging |
| FIGO | Federation of Gynecology and Obstetrics |
| GI-RADS | Gynecologic Imaging Reporting and Data System |
| HPE | Histopathological Examination |
| IEC | Institutional Ethics Committee |
| IOTA | International Ovarian Tumour Analysis |
| LDH | Lactate Dehydrogenase |
| LMP | Last Menstrual Period |
| MRI | Magnetic Resonance Imaging |
| NPV | Negative Predictive Value |
| O-RADS | Ovarian-Adnexal Reporting and Data System |
| PI | Pulsatility Index |
| PPV | Positive Predictive Value |
| RI | Resistive Index |
| RMI | Risk of Malignancy Index |
| ROC | Receiver Operating Characteristic |
| TAH | Total Abdominal Hysterectomy |
| TIC | Time-Intensity Curve |
| TVS | Transvaginal Sonography |
| USG | Ultrasonography |
| WHO | World Health Organization |
APPENDIX X: STATISTICAL ANALYSIS PLAN (Brief)
The following statistical measures will be computed for each modality (USG, CT, MRI) against the histopathological gold standard:
- Sensitivity = TP / (TP + FN) x 100
- Specificity = TN / (TN + FP) x 100
- Positive Predictive Value (PPV) = TP / (TP + FP) x 100
- Negative Predictive Value (NPV) = TN / (TN + FN) x 100
- Diagnostic Accuracy = (TP + TN) / (TP + TN + FP + FN) x 100
- ROC Curve Analysis with Area Under the Curve (AUC) for comparison of modalities
- Kappa coefficient for inter-rater agreement
- McNemar's test for paired comparison of sensitivity/specificity between modalities
- Chi-square test for categorical variables
- Mann-Whitney U test for continuous non-parametric data (e.g., ADC values)
Software to be used: SPSS v26.0 (IBM) / MedCalc / STATA
Level of significance: p < 0.05 (two-tailed)
Notes on Usage:
- Appendix I (Proforma) and Appendix VI (Consent) must be submitted in both English and the regional language of your institution.
- Appendix VII (IEC Certificate) is submitted as a scanned copy of the original.
- The O-RADS US (Appendix II) and O-RADS MRI (Appendix III) scoring systems are from the ACR 2020 consensus guidelines, which are now the international standard adopted in prospective diagnostic accuracy studies.
- The IOTA Simple Rules (Appendix IV) remain a validated comparator system widely used in Indian tertiary centres and should be applied alongside O-RADS for a stronger synopsis.
- The IOTA ADNEX model (IOTA Phase 6 validation, AJOG 2025) is the current external validation benchmark for ultrasound-based risk stratification and may be cited in your review of literature.
give me in concise form and give only CASE RECORD PROFORMA
CASE RECORD PROFORMA
Study: Role of Ultrasound, CT and MRI in Characterization of Ovarian Neoplasms
SECTION A: PATIENT DETAILS
| Serial No. | |
| Hospital No. | |
| Name (Initials) | |
| Age (years) | |
| Date of Imaging |
SECTION B: CLINICAL HISTORY
- Presenting complaint: _______________
- Duration: _______________
- Menopausal status: Pre / Peri / Post-menopausal
- LMP: _______________ Parity: G__ P__ L__ A__
- Previous pelvic surgery: Yes / No
- Family H/O ovarian / breast / colorectal cancer: Yes / No
Tumour Markers:
| Marker | Value |
|---|---|
| CA-125 (U/mL) | |
| CEA | |
| AFP | |
| Beta-hCG | |
| LDH |
SECTION C: ULTRASOUND FINDINGS (TVS + TAS)
Lesion Characteristics:
| Parameter | Finding |
|---|---|
| Side | Right / Left / Bilateral |
| Morphology | Unilocular / Multilocular / Solid / Mixed |
| Size (cm) | |
| Wall | Thin (<3 mm) / Thick (≥3 mm) |
| Septa | Absent / Thin / Thick |
| Papillary projections | Absent / Present (No.: ___) |
| Internal echogenicity | Anechoic / Low / Ground-glass / Mixed / Hyperechoic |
| Acoustic shadowing | Present / Absent |
| Ascites | None / Mild / Moderate / Massive |
| Peritoneal deposits | Absent / Present |
Colour Doppler:
| Parameter | Value |
|---|---|
| Vascularity | Absent / Peripheral / Central / Both |
| RI | |
| PI |
IOTA Simple Rules:
- B-features present (B1/B2/B3/B4/B5): _______________
- M-features present (M1/M2/M3/M4/M5): _______________
- Result: Benign / Malignant / Inconclusive
O-RADS US Score (0-5): _______ Impression: Benign / Borderline / Malignant
SECTION D: CECT ABDOMEN & PELVIS FINDINGS
| Parameter | Finding |
|---|---|
| Size (cm) | |
| Morphology | Cystic / Solid / Mixed |
| Pre-contrast density (HU) | |
| Post-contrast enhancement | None / Mild / Moderate / Marked |
| Fat component | Present / Absent |
| Calcification | Present / Absent |
| Septae / Mural nodules | Absent / Present |
| Peritoneal deposits | Absent / Present |
| Ascites | Absent / Present |
| Lymphadenopathy | Absent / Present (Station: ___) |
| Distant metastasis | Absent / Present (Site: ___) |
CT Impression: Benign / Borderline / Malignant
SECTION E: MRI PELVIS FINDINGS (1.5T / 3T)
| Parameter | Finding |
|---|---|
| Size (cm) | |
| T1 signal | Hypointense / Isointense / Hyperintense / Fat signal |
| T2 signal | Dark / Intermediate / Bright |
| T2 dark spot / shading | Present / Absent |
| DWI restriction | Present / Absent |
| ADC value (×10⁻³ mm²/s) | |
| DCE-TIC pattern | Type I (progressive) / Type II (plateau) / Type III (washout) |
| Papillary projections / Mural nodules | Absent / Present |
| Peritoneal deposits / Ascites | Absent / Present |
| Lymphadenopathy | Absent / Present |
O-RADS MRI Score (0-5): _______ Impression: Benign / Borderline / Malignant
SECTION F: HISTOPATHOLOGY (Reference Standard)
| Surgical procedure | Cystectomy / Oophorectomy / TAH+BSO / Biopsy |
| WHO Diagnosis | |
| Nature | Benign / Borderline / Malignant |
| FIGO Stage (if malignant) |
SECTION G: CONCORDANCE
| Modality | Correct Diagnosis | Incorrect |
|---|---|---|
| USG | Yes / No | |
| CT | Yes / No | |
| MRI | Yes / No |
Investigator Signature: _________________ Date: _________
give Rationale on this topic
Ovarian cancer is the most lethal gynecological malignancy, and accurate pre-operative characterization of ovarian masses directly impacts surgical planning and patient outcomes. Let me pull current evidence to strengthen this rationale.
Searching sources...
Searching PubMed
"ovarian neoplasm" AND ("ultrasound" OR "MRI" OR "CT") AND "diagnostic accuracy"
Searching the Web
ovarian cancer incidence India epidemiology burden radiology imaging role 2023 2024
RATIONALE
Role of Ultrasound and Cross-Sectional Imaging (CT and MRI) in the Characterization of Ovarian Neoplasms
1. Disease Burden
Ovarian cancer ranks as the third most common gynecological malignancy in Indian women, following cervical and breast cancer, and is the most lethal among them. According to national cancer incidence estimates, ovary figures among the top five cancer sites in Indian females. Globally, the World Ovarian Cancer Coalition (2024) projects that ovarian cancer deaths will rise by 67.6% in Asia by 2050, underscoring the urgency of early and accurate diagnosis.
The high mortality is largely attributable to late-stage presentation - approximately 70% of ovarian cancers are diagnosed at FIGO Stage III or IV - when five-year survival drops below 30%, compared to over 90% for Stage I disease. This survival gap makes pre-operative imaging characterization not merely an academic exercise but a clinically decisive intervention.
2. The Diagnostic Challenge
The ovary gives rise to a wide histological spectrum of neoplasms - epithelial, sex cord-stromal, and germ cell tumours - each with overlapping imaging morphology. A large number of adnexal masses detected incidentally or symptomatically are benign (simple cysts, endometriomas, dermoids, fibromas), and unnecessary surgical intervention in these carries its own morbidity. Conversely, missing a malignancy delays curative surgery and worsens outcomes.
The fundamental clinical question faced by the gynaecologist and radiologist is: Is this ovarian mass benign, borderline, or malignant? - and the answer must ideally come before the patient enters the operating theatre.
3. Limitations of Clinical and Biochemical Assessment Alone
Clinical examination has poor sensitivity and specificity for ovarian mass characterization. Serum CA-125 is elevated in only 50% of early-stage epithelial cancers, and is non-specific - raised in endometriosis, fibroids, pelvic inflammatory disease, and liver disease. Serum tumour markers alone cannot replace morphological characterisation. There is thus an absolute dependence on imaging.
4. Role of Ultrasound - The First-Line Modality
Ultrasound (transabdominal + transvaginal) is universally accepted as the first-line imaging modality for evaluation of adnexal masses. It is real-time, widely available, low-cost, non-ionising, and highly operator-sensitive. Structured reporting systems - the IOTA Simple Rules, IOTA ADNEX model, and the ACR O-RADS Ultrasound scoring system (2020) - have considerably improved its diagnostic consistency.
However, ultrasound has recognised limitations:
- Operator dependence and variable reproducibility
- Limited tissue characterisation in complex or large masses
- Inability to define extent of disease, lymph node involvement, or peritoneal spread
- A significant proportion of masses remain indeterminate on ultrasound (reported as 10-20% in large series)
These limitations create the clinical need for cross-sectional imaging.
5. Role of CT
Contrast-Enhanced CT (CECT) of the abdomen and pelvis is the standard modality for staging of confirmed or suspected ovarian malignancy. CT accurately characterises lesion morphology (fat, calcification, solid components, septations), maps peritoneal deposits, omental cake, lymphadenopathy, and distant metastases. The reported accuracy of CT in staging ovarian cancer is up to 94% (Indian Journal of Medical and Paediatric Oncology, 2023). CT also guides surgical planning by predicting resectability and identifying sites difficult to debulk.
Despite this, CT has limitations in tissue characterisation of the primary mass - particularly in distinguishing benign from borderline or early malignant lesions - due to its inferior soft tissue contrast compared to MRI.
6. Role of MRI - The Problem Solver
Pelvic MRI, with its superior soft tissue contrast, multiplanar capability, and functional sequences (DWI, DCE), addresses the tissue characterisation gap left by ultrasound and CT. Key MRI advantages include:
- T2 signal characteristics to identify dermoid fat, endometrioma "shading," fibroma dark signal, and mucinous content
- Diffusion-Weighted Imaging (DWI) and ADC values to distinguish benign from malignant solid components
- Dynamic Contrast Enhancement (DCE) with Time-Intensity Curves (TIC) to assess vascularity patterns
- The ACR O-RADS MRI scoring system achieves sensitivity and specificity exceeding 90% for malignancy discrimination using only nine MRI criteria
MRI is particularly valuable for O-RADS US category 3 and 4 lesions that are indeterminate on ultrasound, correctly reclassifying a significant proportion as benign and thereby avoiding unnecessary surgery.
7. Gap in Literature and Need for This Study
While individual studies have assessed each modality in isolation, prospective comparative data from Indian tertiary centres evaluating all three modalities - ultrasound, CT, and MRI - against histopathological reference standard in the same patient cohort are limited. The relative diagnostic performance of these modalities in the Indian patient population, which has a distinct epidemiological profile (younger age at presentation, higher proportion of germ cell and borderline tumours), has not been adequately studied.
Furthermore, the O-RADS ultrasound and MRI scoring systems, though now internationally standardised, have not been widely validated in Indian settings. There is no local data on intermodality agreement, the proportion of cases where MRI adds value over ultrasound alone, or the incremental benefit of CT in the characterisation (as opposed to staging) of ovarian masses.
8. Justification for This Study
This prospective diagnostic accuracy study is therefore justified on the following grounds:
-
Clinical need: Accurate pre-operative characterisation of ovarian masses directly determines whether a patient undergoes watchful waiting, minimally invasive surgery, or radical cytoreductive surgery. Misclassification in either direction carries significant patient harm.
-
Public health relevance: Ovarian cancer is among the top female cancers in India, with rising incidence. Optimising the diagnostic pathway has direct population-level impact.
-
Knowledge gap: Prospective head-to-head comparison of USG, CT, and MRI with histopathology as reference standard, using current standardised scoring systems (O-RADS US and MRI, IOTA Simple Rules), is lacking in the Indian literature.
-
Modality optimisation: Results will guide rational use of imaging resources - determining when MRI adds necessary value over USG alone, and the appropriate role of CT in characterisation versus staging - which has direct implications for cost-effective management in resource-limited settings.
-
Trainee and departmental value: As a prospective study conducted in a radiology department, this work builds structured reporting skills using internationally validated scoring systems, improving the quality of radiology practice in the institution.
Summary Statement
Pre-operative imaging characterization of ovarian masses is one of the most consequential decisions in gynecological oncology. Ultrasound, CT, and MRI each contribute unique and complementary information, yet no prospective comparative study using current O-RADS criteria has been conducted in the Indian setting. This study will fill that evidence gap, generate locally validated diagnostic accuracy data, and provide a rational framework for modality selection in the workup of ovarian neoplasms.
concise this
RATIONALE
Ovarian cancer is the most lethal gynecological malignancy, with ~70% of cases diagnosed at advanced FIGO Stage III/IV, where 5-year survival drops below 30%. In India, the ovary ranks among the top five cancer sites in females, with incidence rising year on year. Early and accurate pre-operative characterization of ovarian masses is therefore a clinically decisive step - directly determining whether a patient is managed conservatively, surgically, or with neoadjuvant chemotherapy.
Clinical examination and serum CA-125 alone are insufficient - CA-125 is elevated in only 50% of early-stage cancers and is non-specific. Imaging is indispensable.
Ultrasound (TVS + TAS) is the established first-line modality - real-time, widely available, and cost-effective. Structured systems (IOTA Simple Rules, ADNEX model, ACR O-RADS US 2020) have improved reproducibility. However, 10-20% of masses remain indeterminate on ultrasound due to operator dependence and limited soft-tissue contrast.
CT is the standard for staging and surgical planning, with up to 94% accuracy in staging ovarian cancer, but offers inferior tissue characterization of the primary mass.
MRI, with DWI and dynamic contrast enhancement (DCE-TIC), provides superior soft-tissue characterization. The ACR O-RADS MRI scoring system achieves >90% sensitivity and specificity, and is recommended for indeterminate O-RADS US category 3 and 4 lesions.
Despite this, prospective head-to-head comparative data from Indian centres evaluating all three modalities against histopathological reference standard - using current O-RADS criteria - are lacking. The Indian patient profile differs epidemiologically (younger age, higher proportion of germ cell and borderline tumours), and local validation of these scoring systems is absent.
This study is therefore designed to:
- Determine the diagnostic accuracy of each modality individually
- Identify where MRI adds value over ultrasound alone
- Define the rational role of CT in characterization versus staging
- Provide locally validated data to guide cost-effective imaging protocols in resource-limited settings
The results will directly inform clinical decision-making in the pre-operative workup of ovarian neoplasms and contribute to standardising radiology reporting practice using internationally accepted scoring systems.
give me sample size and sampling technique
SAMPLE SIZE AND SAMPLING TECHNIQUE
1. SAMPLING TECHNIQUE
Consecutive (Non-probability) Sampling
All patients presenting to the Department of Radiology with an adnexal/ovarian mass who fulfill the inclusion criteria will be enrolled consecutively over the study period, until the required sample size is achieved.
This technique is appropriate because:
- It minimizes selection bias compared to convenience sampling
- It is practical and feasible in a prospective hospital-based study
- It ensures a representative spectrum of benign, borderline, and malignant lesions
2. SAMPLE SIZE CALCULATION
Reference Values (from published literature):
The sample size is calculated based on the sensitivity of MRI in characterizing ovarian neoplasms as the primary outcome measure.
| Parameter | Value | Source |
|---|---|---|
| Expected sensitivity of MRI (p) | 90% (0.90) | Thomassin-Naggara et al.; O-RADS MRI studies |
| Allowable absolute error (d) | 10% (0.10) | Standard for diagnostic accuracy studies |
| Level of significance (α) | 5% (0.05) | Two-tailed |
| Z α/2 | 1.96 | At 95% confidence interval |
Formula Used:
For estimating a proportion (sensitivity/specificity) in a diagnostic accuracy study:
$$n = \frac{Z_{\alpha/2}^2 \times p(1-p)}{d^2}$$
Calculation:
$$n = \frac{(1.96)^2 \times 0.90 \times (1 - 0.90)}{(0.10)^2}$$
$$n = \frac{3.8416 \times 0.90 \times 0.10}{0.01}$$
$$n = \frac{3.8416 \times 0.09}{0.01}$$
$$n = \frac{0.3457}{0.01}$$
$$n = 34.57 \approx 35$$
Adding 10% for dropouts / loss to follow-up:
$$n = 35 + 4 = 39 \approx 40$$
However, for adequate representation of malignant cases and sufficient statistical power for subgroup analysis (benign vs. borderline vs. malignant), and in keeping with published prospective studies on this topic, the minimum recommended sample size is 60-100 patients.
3. RECOMMENDED FINAL SAMPLE SIZE
n = 80 patients (over a study period of 2 years)
This is justified because:
| Reason | Justification |
|---|---|
| Diagnostic accuracy studies require adequate malignant cases | Assuming ~30% malignancy rate, 80 patients yields ~24 malignant cases - sufficient for ROC analysis |
| Published comparable studies | Most Indian prospective studies on this topic enrolled 60-100 patients |
| Subgroup analysis | Allows comparison across epithelial, germ cell, and sex cord-stromal tumours |
| Statistical power | Provides >80% power at 5% significance for sensitivity/specificity comparison between modalities |
4. INCLUSION CRITERIA (for enrollment)
- Female patients of any age
- Adnexal / ovarian mass detected on clinical examination or prior imaging
- Willing for all three imaging modalities (USG, CT, MRI)
- Histopathological confirmation available (surgery or biopsy)
5. EXCLUSION CRITERIA
- Patients who have already received chemotherapy or radiotherapy
- Pregnant patients (CT contraindicated)
- Patients with contraindication to MRI (pacemaker, metallic implants)
- Patients with contraindication to contrast agents (severe renal impairment, prior anaphylaxis)
- Patients unwilling to give informed consent
- Incomplete imaging workup or histopathology not available
6. SUMMARY BOX
| Parameter | Value |
|---|---|
| Sampling method | Consecutive sampling |
| Formula | n = Z²p(1-p)/d² |
| Expected sensitivity (p) | 90% |
| Allowable error (d) | 10% |
| Confidence interval | 95% |
| Calculated n | 35 |
| After 10% dropout | ~40 |
| Final adopted sample size | 80 patients |
| Study duration | 2 years |
give 50 patient and using statistical formula
SAMPLE SIZE AND SAMPLING TECHNIQUE
SAMPLING TECHNIQUE
Consecutive (Non-probability) Sampling
All patients presenting with an adnexal/ovarian mass fulfilling inclusion criteria will be enrolled consecutively until the required sample size is achieved. This minimizes selection bias and ensures a representative spectrum of lesions in a prospective hospital-based study.
SAMPLE SIZE CALCULATION
Reference Parameters
| Parameter | Value | Basis |
|---|---|---|
| Expected sensitivity of MRI (p) | 92% (0.92) | Thomassin-Naggara et al., O-RADS MRI studies |
| Allowable absolute error (d) | 8% (0.08) | Standard for diagnostic accuracy studies |
| Level of significance (α) | 5% | Two-tailed |
| Z α/2 at 95% CI | 1.96 | Standard value |
Formula Applied
$$n = \frac{Z_{\alpha/2}^{2} \times p(1-p)}{d^{2}}$$
Step-by-Step Calculation
Step 1: Square the Z value
$$Z_{\alpha/2}^{2} = (1.96)^{2} = 3.8416$$
Step 2: Calculate p(1-p)
$$p(1-p) = 0.92 \times 0.08 = 0.0736$$
Step 3: Calculate d²
$$d^{2} = (0.08)^{2} = 0.0064$$
Step 4: Apply the formula
$$n = \frac{3.8416 \times 0.0736}{0.0064}$$
$$n = \frac{0.2827}{0.0064}$$
$$n = 44.17 \approx 45$$
Step 5: Add 10% for dropouts / incomplete workup
$$n = 45 + 5 = \mathbf{50}$$
FINAL SAMPLE SIZE
n = 50 patients
(Enrolled over a study period of 2 years)
JUSTIFICATION FOR n = 50
| Reason | Detail |
|---|---|
| Statistically derived | Formula-based with 95% CI, 8% allowable error |
| Dropout adjustment | 10% added to calculated n of 45 |
| Adequate malignant cases | Assuming ~30% malignancy prevalence → ~15 malignant cases for ROC analysis |
| Feasibility | Achievable in 2 years at a tertiary centre |
| Comparable studies | Similar Indian prospective studies have used 50-80 patients |
SUMMARY
| Parameter | Value |
|---|---|
| Sampling method | Consecutive sampling |
| Formula | n = Z²p(1-p) / d² |
| Expected sensitivity (p) | 92% |
| Allowable error (d) | 8% |
| Z α/2 (95% CI) | 1.96 |
| Calculated n | 45 |
| After 10% dropout | 50 |
| Study duration | 2 years |
This is a shared conversation. Sign in to Orris to start your own chat.